每年專案
指紋
過去五年中的合作和熱門研究領域
概要
-
探討SH3RF3在大腸癌中作為克服Cetuximab耐藥性並預防KRAS突變之生物標誌物及靶點
Chang, T.-C. (PI)
8/1/25 → 7/31/26
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
破解及針對調控基質開關以克服大腸直腸癌中微衛星穩定 CMS第4型免疫檢查點抑制劑抗藥性之轉譯研究(2/3)
Huang, Y.-J. (PI)
8/1/25 → 7/31/26
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
-
A Predictive Model for Anastomotic Complications After Sphincter-Preserving Surgery for Rectal Cancer: Integrating Clinical and Anatomical Risk Factors
Kuo, C. Y., Lee, C. Y., Kung, C. H., Ngu, J. C. Y. & Kuo, L. J., 2025, 於: Diseases of the Colon and Rectum. 10.1097/DCR.0000000000003938.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
Chia, J. W. K., Segelov, E., Deng, Y., Ho, G. F., Wang, W., Han, S., Sharma, A., Ding, K., Chen, G., Jeffery, M. G., Tham, C. K., Ahn, J. B., Nott, L., Zielinski, R., Chao, T.-Y., van Hagen, T., Wei, P.-L., Day, F., Mehta, S. & Yau, T. 及其他10, , 3月 2025, 於: The Lancet Gastroenterology and Hepatology. 10, 3, p. 198-209 12 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
9 引文 斯高帕斯(Scopus) -
Clinical impact of pharmacogenetic risk variants in a large chinese cohort
Wei, C. Y., Wen, M. S., Cheng, C. K., Sheen, Y. J., Yao, T. C., Lee, S. L., Wu, J. Y., Tsai, M. F., Li, L. H., Chen, C. H., Fann, C. S. J., Yang, H. C., Huang, Y. T., Chen, H. H., Liu, Y. M., Yeh, E. C., Peng, Y. C., Wang, S. J., Chen, S. P. & Tsai, M. T. 及其他104, , 12月 2025, 於: Nature Communications. 16, 1, 6344.研究成果: 雜誌貢獻 › 文章 › 同行評審
3 引文 斯高帕斯(Scopus)
資料集
-
Additional file 1: of Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial
Tsai, H.-L. (Contributor), Sung, Y.-C. (Contributor), Tang, H.-C. (Contributor), Yeh, Y.-S. (Contributor), Wei, P.-L. (Contributor), Wang, J.-Y. (Contributor) & Huang, C.-W. (Creator), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3751544_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3751544_d1.v1
資料集: Dataset
-
Additional file 2: Figure S1. of Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways
Huynh, T.-T. (Contributor), Tzeng, Y.-M. (Contributor), Yen, Y. (Creator), Yang, C.-K. (Contributor), Wu, A. T. (Creator), Meng, T.-C. (Contributor), Whang-Peng, J. (Creator), Wei, P.-L. (Contributor), Hsiao, M. (Creator) & Huang, Y.-J. (Contributor), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3704533_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3704533_d1.v1
資料集: Dataset
-
Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways
Huang, Y.-J. (Contributor), Yang, C.-K. (Contributor), Wei, P.-L. (Contributor), Huynh, T.-T. (Contributor), Whang-Peng, J. (Creator), Meng, T.-C. (Contributor), Hsiao, M. (Creator), Tzeng, Y.-M. (Contributor), Wu, A. T. (Creator) & Yen, Y. (Creator), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3704533.v1, https://doi.org/10.6084%2Fm9.figshare.c.3704533.v1
資料集: Dataset